Rhythm Pharma's Imcivree Soars, Driving Revenue Surge

Rhythm Pharmaceuticals stock surged 8% on Tuesday, following robust Q1 earnings. Their lead drug Imcivree boosted revenue to $60.1 million, nearly doubling last years $32.7 million and exceeding analyst predictions. Despite a wider net loss of $56.7 million, investors were thrilled by the potential of this specialized weight-loss treatment, now approved for acquired hypothalamic obesity. Early patient start forms and European sales growth further buoyed optimism. Rhythms pipeline expansion for Imcivrees additional uses promises a steady rhythm in biotech. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/41eacfcc3c6cb106